3G6 Stock Chart & Stats
€17.50
€0.40(2.20%)
At close: 4:00 PM EST
€17.50
€0.40(2.20%)
Day’s Range― - ―
52-Week Range€11.90 - €19.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€902.43M
Enterprise Value€127.86B
Total Cash (Recent Filing)€19.87B
Total Debt (Recent Filing)€5.17B
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 14, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-112.69
Shares Outstanding65,817,420
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.94Price Target Upside19.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.29
Revenue Forecast (FY)€163.94M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginsSustained TTM revenue growth (+76.5%) paired with persistently high gross margins (~74%) indicate durable demand and a scalable cost structure. Over 2–6 months this supports margin recovery if operating expenses normalize and underpins long‑term cash generation once operating losses are addressed.
Low Leverage / Strong CapitalizationVery low TTM debt-to-equity (~0.10) and a sizable equity base (~¥50B) provide financial flexibility to fund R&D, commercial expansion or bridge near-term losses without immediate refinancing. This reduces bankruptcy risk and preserves strategic optionality over the medium term.
Proven Cash Generation In 2023Historical ability to deliver strong positive cash flow in 2023 shows the business model can generate free cash when conditions align. That track record signals the company can revert to internal funding for growth if revenue stability and margin controls are restored, lowering long‑term funding risk.
Bears Say
Negative Operating & Free Cash FlowSustained negative operating and free cash flow (~-¥2.5B / -¥2.9B TTM) forces reliance on cash reserves or external financing, increasing dilution and execution risk. Over several months this constrains reinvestment capacity and raises the possibility of capital raises if losses persist.
Negative Profitability / Operating LossesA negative TTM net margin (-8.5%) and recent operating losses indicate weakened earnings power and negative returns on capital. Without sustained margin recovery, shareholder returns and reinvestment prospects remain impaired, making durable profitability an open execution risk.
Balance Sheet Volatility In Prior YearsPrior-year balance sheet volatility, including materially higher debt-to-equity in 2024, signals potential episodic funding stress under adverse conditions. This history raises the probability that the company may need to increase leverage or dilute equity again if cash flow weaknesses continue.
GNI Group News
3G6 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was €11.90 and its highest was €19.60 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is €902.43M.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Aug 14, 2026 which is in 9 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on May 15, 2026. The company reported -€0.205 earnings per share for the quarter, missing the consensus estimate of -€0.015 by -€0.19.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -0.33.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 65,817,420 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -€0.205 in its last earnings report, missing expectations of -€0.015. Following the earnings report the stock price went down -3.145%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in DE:3G6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
3G6 Stock 12 Month Forecast
Average Price Target
€20.94
▲(19.65% Upside)